The funding will support clinical development and drug discovery programmes derived from academic research.
"We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their additional support, as well as welcoming new shareholders to the Company,"
The funding round was backed by M&G Investments and Van Tuyl Companies to accelerate product development and international expansion.
"To have such a strong close to our Series C strategic funding round is a testament to the momentum built by Dr. Christmas and the team at Envisics. We were an early investor in Envisics, and we welcome the very impressive roster of returning and new investors in this round."